Page 1549 - Williams Hematology ( PDFDrive )

1524 Part XI: Malignant Lymphoid Diseases Chapter 91: Acute Lymphoblastic Leukemia 1525

UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet 169. Chessells JM, Harrison G, Lilleyman JS, et al: Continuing (maintenance) therapy in
345:143, 1995. lymphoblastic leukaemia: Lessons from MRC UKALL X. Medical Research Council
144. Pui CH, Sandlund JT, Pei D, et al: Improved outcome for children with acute lympho- Working Party in Childhood Leukaemia. Br J Haematol 98:945, 1997.
blastic leukemia: Results of Total Therapy Study XIIIB at St. Jude Children’s Research 170. Relling MV, Hancock ML, Boyett JM, et al: Prognostic importance of 6-mercaptopurine
Hospital. Blood 104:2690, 2004. dose intensity in acute lymphoblastic leukemia. Blood 93:2817, 1999.
145. Loh ML, Goldwasser MA, Silverman LB, et al: Prospective analysis of TEL/AML1-pos- 171. Schmiegelow K, Glomstein A, Kristinsson J, et al: Impact of morning versus evening
itive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with
Blood 107:4508, 2006. acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology
146. Asselin BL, Devida M, Wang C, et al: Effectiveness of high-dose methotrexate in T-cell (NOPHO). J Pediatr Hematol Oncol 19:102, 1997.
lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: A randomized 172. Rivard GE, Lin KT, Leclerc JM, David M: Milk could decrease the bioavailability of
study by the Children’s Oncology Group (POG 9404). Blood 118:874, 2011. 6-mercaptopurine. Am J Pediatr Hematol Oncol 11:402, 1989.
147. Galpin AJ, Schuetz JD, Masson E, et al: Differences in folylpolyglutamate synthetase 173. Farrow AC, Buchanan GR, Zwiener RJ, et al: Serum aminotransferase elevation dur-
and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic ing and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol
lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation 15:1560, 1997.
and cytotoxicity. Mol Pharmacol 52:155, 1997. 174. Evans WE, Horner M, Chu YQ, et al: Altered mercaptopurine metabolism, toxic effects,
148. Mikkelsen TS, Sparreboom A, Cheng C, et al: Shortening infusion time for high-dose and dosage requirement in a thiopurine methyltransferase-deficient child with acute
methotrexate alters antileukemic effects: A randomized prospective clinical trial. J Clin lymphocytic leukemia. J Pediatr 119:985, 1991.
Oncol 29:1771, 2011. 175. Relling MV, Hancock ML, Rivera GK, et al: Mercaptopurine therapy intolerance and
149. Kager L, Cheok M, Yang W, et al: Folate pathway gene expression differs in subtypes of heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001,
acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin 1999.
Invest 115:110, 2005. 176. Pui CH, Relling MV: Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J
150. Hoelzer D, Gökbuget N: Chemoimmunotherapy in acute lymphoblastic leukemia. Haematol 109:13, 2000.
Blood Rev 26:25, 2012. 177. Schmiegelow K, Al-Modhwahi I, Andersen MK, et al: Methotrexate/6-mercaptopurine
151. Thomas DA, O’Brien S, Faderl S, et al: Chemoimmunotherapy with a modified maintenance therapy influences the risk of a second malignant neoplasm after child-
hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia hood acute lymphoblastic leukemia: Results from the NOPHOALL-92 study. Blood
chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 113:6077, 2009.
28:3880, 2010. 178. Relling MV, Rubnitz JE, Rivera GK, et al: High incidence of secondary brain tumours
152. Rowe JM, Buck G, Burnett AK, et al. for the ECOG and the MRC/NCRI Adult Leuke- after radiotherapy and antimetabolites. Lancet 354:34, 1999.
mia Working Party: Induction therapy for adults with acute lymphoblastic leukemia: 179. Cheok MH, Pottier N, Kager L, Evans WE: Pharmacogenetics in acute lymphoblastic
Results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ leukemia. Semin Hematol 46:39, 2009.
ECOG E2993. Blood 106:3760, 2005. 180. Relling MV, Ramsey LB: Pharmacogenomics of acute lymphoid leukemia: New insights
153. Huguet F, Leguay T, Raffoux E, et al: Pediatric-inspired therapy in adults with Philadel- into treatment toxicity and efficacy. Hematology Am Soc Hematol Educ Program 2013:126,
phia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study. 2013.
J Clin Oncol 27:911, 2009. 181. Jacobs SS, Stork LC, Bostrom BC, et al: Substitution of oral and intravenous thiogua-
154. Ludwig WD, Rieder H, Bartram CR, et al: Immunophenotypic and genotypic features, nine for mercaptopurine in a treatment regimen for children with standard risk acute
clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic lymphoblastic leukemia: A collaborative Children’s Oncology Group/National Cancer
leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89. Blood Institute pilot trial (CCG-1942). Pediatr Blood Cancer 49:250, 2007.
92:1898, 1998. 182. Vora A, Mitchell CD, Lennard L, et al: Toxicity and efficacy of 6-thioguanine versus
155. Nakano TA, Hunger SP: Blood consult: Therapeutic strategy and complications 6-mercaptopurine in childhood lymphoblastic leukaemia: A randomised trial. Lancet
in the adolescent and young adult with acute lymphoblastic leukemia. Blood 368:1339, 2006.
119:4372, 2012. 183. Eden T, Pieters R, Richards S; Childhood Acute Lymphoblastic Leukaemia Collaborative
156. Stock W, La M, Sanford B, et al: What determines the outcomes for adolescents and Group (CALLCG): Systematic review of the addition of vincristine plus steroid pulses
young adults with acute lymphoblastic leukemia treated on cooperative group proto- in maintenance treatment for childhood acute lymphoblastic leukaemia—An individual
cols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B patient data meta-analysis involving 5,659 children. Br J Haematol 149:722, 2010.
studies. Blood 112:1646, 2008. 184. Mattano LA Jr, Devidas M, Nachman JB, et al. for the Children’s Oncology Group:
157. Boissel N, Auclerc MF, Lhéritier V, et al: Should adolescents with acute lymphoblas- Effect of alternate-week versus continuous dexamethasone scheduling on the risk of
tic leukemia be treated as old children or young adults? Comparison of the French osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: Results from
FRALLE-93 and LALA-94 trials. J Clin Oncol 21:774, 2003. the CCG-1961 randomised cohort trial. Lancet Oncol 13:906, 2012.
158. Ribera JM, Oriol A, Sanz MA, et al: Comparison of the results of the treatment of ado- 185. Lange BJ, Bostrom BC, Cherlow JM, et al: Double-delayed intensification improves
lescents and young adults with standard-risk acute lymphoblastic leukemia with the event-free survival for children with intermediate-risk acute lymphoblastic leukemia:
Programa Espanol de Tratamiento en Hematologia Pediatric-based protocol 96. J Clin A report from the Children’s Cancer Group. Blood 99:825, 2002.
Oncol 26:1843, 2008. 186. Pui CH, Thiel E: Central nervous system disease in hematologic malignancies: Histori-
159. Nachman JB, La MK, Hunger SP, et al: Young adults with acute lymphoblastic cal perspective and practical applications. Semin Oncol 36(4 Suppl 2):S2, 2009.
leukemia have an excellent outcome with chemotherapy alone and benefit from inten- 187. Vilmer E, Suciu S, Ferster A, et al: Long-term results of three randomized trials (58831,
sive postinduction treatment: A report from the Children’s Oncology Group. J Clin Oncol 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report.
27:5189, 2009. Leukemia 14:2257, 2000.
160. Pui CH, Pei D, Campana D, et al: Improved prognosis for older adolescents with acute 188. Manera R, Ramirez I, Mullins J, Pinkel D: Pilot studies of species-specific chemother-
lymphoblastic leukemia. J Clin Oncol 29:386, 2011. apy of childhood acute lymphoblastic leukemia using genotype and immunopheno-
161. Schafer ES, Hunger SP: Optimal therapy for acute lymphoblastic leukemia in adoles- type. Leukemia 14:1354, 2000.
cents and young adults. Nat Rev Clin Oncol 8:417, 2011. 189. Conter V, Schrappe M, Aric M, et al: Role of cranial radiotherapy for childhood T-cell
162. Deangelo DJ, Stevenson KE, Dahlberg SE, et al: Long-term outcome of a pediatric-inspired acute lymphoblastic leukemia with high WBC count and good response to prednisone.
regimen used for adults ages 18 to 50 with newly diagnosed acute lymphoblastic leukemia. Associazione Italiana Ematalogia Oncologia Pediatrica and the Berlin-Frankfurt-Munster
Leukemia 29:526, 2015. groups. J Clin Oncol 15:2786, 1997.
163. Riehm H, Gadner H, Henze G, et al: Results and significance of six randomized trials in 190. Pui CH, Campana D, Pei D, et al: Treating childhood acute lymphoblastic leukemia
four consecutive ALL-BFM studies. Haematol Blood Transfus 33:439, 1990. without prophylactic cranial irradiation. N Engl J Med 360:2730, 2009.
164. Toyoda Y, Manabe A, Tsuchida M, et al: Six months of maintenance chemotherapy 191. Veerman AJ, Kamps WA, ven den Berg H, et al: Dexamethasone-based therapy for
after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol childhood acute lymphoblastic leukaemia: Results of the prospective Dutch Childhood
18:1508, 2000. Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol 10:957, 2009.
165. Childhood ALL Collaborative Group: Duration and intensity of maintenance chemo- 192. Richards S, Pui CH, Gayon P; Childhood Acute Lymphoblastic Leukemia Collaborative
therapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12,000 ran- Group (CALLCG): Systematic review and meta-analysis of randomized trials of central
domised children. Lancet 347:1783, 1996. nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatr
166. Sather H, Miller D, Nesbit M, et al: Differences in prognosis for boys and girls with Blood Cancer 60:185, 2013.
acute lymphoblastic leukaemia. Lancet 1:739, 1981. 193. Matloub Y, Lindemulder S, Gaynon PS, et al: Intrathecal triple therapy decreases cen-
167. The Medical Research Council’s Working Party on Leukaemia in Childhood: Dura- tral nervous system relapse but fails to improve event-free survival when compared to
tion of chemotherapy-in-childhood acute lymphoblastic leukaemia. Med Pediatr Oncol intrathecal methotrexate: Results of the Children’s Cancer Group (CCG) 1952 study for
10:511, 1982. standard-risk acute lymphoblastic leukemia. A report from the Children’s Oncology
168. Schmiegelow K, Schroder H, Gustafsson G, et al: Risk of relapse in childhood acute Group. Blood 108:1165, 2006.
lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabo- 194. Oliansky DM, Larson RA, Weisdorf D, et al: The role of cytotoxic therapy with hemato-
lites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and poietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia:
Oncology. J Clin Oncol 13:345, 1995. Update of the 2006 evidence-based review. Biol Blood Marrow Transplant 18:18, 2012.

Kaushansky_chapter 91_p1505-1526.indd 1524 9/21/15 12:20 PM